1)   

E. Kovacs, D. Stucki and P. Tschumi.

The DNA-repair synthesis in healthy 
daughters of breast cancer patients. ECCO-3, Stockholm (1985).

2)

E. Kovacs and D. Stucki.

Impaired DNA-repair synthesis in lymphocytes of breast cancer patients. ECCO-3, Stockholm (1985).

3)

E. Kovacs, A. Almendral and H. Ludwig.

Deficiency in the DNA-repair synthesis:Is it hereditary or acquired?  ECCO-4,
Madrid (1987).

4)

E. Kovacs, A. Almendral and H. Ludwig.

Does chemo/radiotherapy affect the DNA-repair? First International Congress on management of metastatic disease. Lyon/France (1988).

5)

E. Kovacs and A. Almendral.

Characterisation of DNA-repair in cancer patients. ECCO-5, London (1989).

6)

E Kovacs

Improvement of DNA-repair in breast cancer patients during therapy. ECCO-5,
London (1989).

7)

E. Kovacs

DNA-repair and carcinogenesis. 15th International Cancer Congress, 
Hamburg (1990).

8)

M. Meichsner, E. Kovacs and H. Ludwig.

lnterleukin-2 Rezeptoren in der Dezidua. 48. Kongress der Deutschen Gesellschaft für Gynäkologie & Geburtshilfe, Hamburg (1990).

9)

T. Hajto, K. Hostanska and E. Kovacs.

Does mistletoe extracts possess the immunomodulatory potency without optimised lectin activity? 4th International Congress on Phytotherapy, Munich (1992).

10)      

E. Kovacs and H. Ludwig.

Relationship of the DNA repair to clinical state in cancer patients. Deutscher Krebskongress, Berlin (1992).

11)

E. Kovacs

The effect of Interferon-alpha treatment on the DNA-repair in cancer patients having chemotherapy. 1st Baltic Congress of Oncology and Radiology, Tallin (1994).

12)

E. Kovacs, JJ. Kuehn, M. Werner and J. Hoffmann.

Effect of lscador® on DNA repair after radiation or cyclophosphamide. Correlation with IFN-gamma production. Gemeinsame Jahrestagung der Deutschen und der Oesterreichischen Gesellschaft für Hämatologie und Onkologie, Hamburg. Onkologie Supplement 2, Vol 18 (1995). 

13)

E. Kovacs, JJ. Kuehn, M. Werner and J. Hoffmann.

Effect of Iscador treatment on DNA repair in cancer patients. Correlation with immunological parameters. Annual Congress of the German and the Austrian Society of Hematology and Oncology, Düsseldorf. Annals of Hematology Supplement II, Vol 73 (1996).

14)

E. Kovacs, JJ. Kuehn, M. Werner and J. Hoffmann.

Die Wirkung einer Behandlung mit Viscum album extrakt (Iscador) auf die DNA-Reparatur der Lymphozyten bei Karzinompatienten. Forschende Komplementärmedizin 
Supplement 1, Vol 3 (1998).

15)

E. Kovacs

Serum levels of IL-12, IL-6 and the production of IFN-gamma, IL-2, IL-4 
by peripheral blood mononuclear cell in cancer patients treated with Viscum album 
extract. 10th International AEK Congress, Heidelberg. J Cancer Research and 
Clinical Oncology Supplement 1, Vol 125 (1999).

16)

E. Kovacs

Serum levels of IL-6, slL-6 receptor and sgp130 in cancer patients. 3rd International Dresden Symposium on Immunotherapy of Cancer, Dresden (2000).

17)

E. Kovacs

Investigation of IL-6, IL-12, IFN-gamma, IL-16 and IL-4 in serum of cancer patients treated with Viscum album extract (lscador®). 3rd International Congress on Phytomedicine, Munich. Phytomedicine, Supplement II, Vol 7 (2000).

18)

E. Kovacs

Beneficial effects of Viscum album (VA) extract therapy in cancer patients. Relation with interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130).
12th international AEK congress, Würzburg (2003).

19)

E. Kovacs

Mistletoe (Viscum album) extract or Vincristine? A comparative study. 
International Congress on Complementary Medicine Research, Munich, (2007).   

20)

E. Kovacs, S. Link and U. Toffol-Schmidt.

The effect of Viscum album extract and Vincristine on the proliferation in several multiple myeloma cell lines. The function of IL-6 and IL-10 in the proliferation. 4th Mistletoe Symposium, Nonnweiler-Oetzenhausen.  Phytomedicine Supplement VII (2007).

21)

E. Kovacs

Can IL-6 inhibit the proliferation of human multiple myeloma cell lines? Is IL-6 a
pro-apoptotic factor in these cell lines? American Association for Cancer Research, Tumor Immunology: New Perspectives. Miami (2008).

22)

E. Kovacs

Multiple myeloma: Combination therapy with Interleukin-6 antibody and Interleukin-6 receptor antibody. 1st International Congress for Controversies in Hematology,
Rome (2010).

23)

E. Kovacs-Benke

The role of cytokines IL-6, IL-10 and TNF-alpha in the pathogenesis of multiple myeloma. Clinical significance. Therapeutic modalities. Oral presentation at the 1st Annual International Symposium of Hematology, Beijing, China (2012).

24)

E. Kovacs-Benke

Combination of Interleukin-6 Antibody and Interleukin-6 Receptor Antibody in the Therapy of Multiple Myeloma. ESH International Conference on MULTIPLE MYELOM, Dublin, Ireland (2013).

25)

E. Kovacs-Benke

Cytokines in the Tumor Pathophysiology. Therapeutic Intervention. International Drug Discovery Science and Technology - Japan, Osaka (2017)

26)

E. Kovacs-Benke

Monitoring of Interleukin-6, Interleukin-10 and Tumour Necrosis Factor-alpha, as proliferative factors in Multiple Myeloma. European Myeloma Network Meeting, Turin (2018)

27)

E. Kovacs-Benke

Cytokine-Mapping in Colorectal-Cancer. Therapeutic intervention, 13th European Colorectal Congress of St.Gallen, 01-05.12.2019

28)

E. Kovacs-Benke

Monitoring and Mapping of the Systemic Lupus Erythematosus, 12th European Lupus Meeting, 25-27 March 2020 in Bruges, Belgium